Another failure on the dementia front. This time a drug targeting frontotemporal dementia. The drug raised progranulin levels, the biochemical target, but did not improve outcomes compared to placebo.
Dementia continues to be a hard nut to crack
www.statnews.com/2025/10/21/a...
statnews.com
Alector's dementia drug fails to slow patient decline in late-stage trial
An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage study, the company announced Tuesday.
